Starting in 1989, Olivieri was part of a group evaluating the use of a drug,
deferiprone, in treating persons with the blood disorder
thalassaemia. Olivieri's scientific findings, which sparked the controversy, have been challenged on the basis of data from clinical trials conducted by Apotex.
Deferiprone is approved for use in over 50 countries, but not in
Canada. It was approved in the US in 2011 under the FDA's accelerated approval program. An investigation commissioned by the
Canadian Association of University Teachers (CAUT) revealed that one of Olivieri's critics,
Gideon Koren, had anonymously sent disparaging letters about Olivieri to the media and colleagues. Koren initially denied responsibility, but substantial DNA evidence tied him to the letters, and he was reprimanded. Olivieri has advocated greater
academic freedom and called for less control of research by
pharmaceutical companies. This situation was publicised extensively and was investigated by the Canadian Association of University Teachers. ==Awards and honours==